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Recently, the UK’s Driver & Vehicle Licencing Agency
(DVLA) published updated guidance for medical profes-
sionals on assessing ﬁtness to drive.1 This included updates
for adults with congenital heart disease (ACHD) and a new
section for those with pulmonary hypertension. There is
some overlap in these conditions, with pulmonary arterial
hypertension (PAH) aﬀecting 5–10% of congenital heart
disease patients. Both PAH and ACHD are the remit of
the specialist, and in both conditions social independence
and psychological wellbeing are key goals of care. Driving
can enhance an individual’s independence by facilitating
engagement in social roles, including employment, family
life and peer relationships. In the presence of medical con-
ditions that can signiﬁcantly aﬀect exercise tolerance, this
freedom must be balanced against the risk of a sudden dis-
abling event.
In the new guidance, anyone with ACHD and symptoms,
including any severity of palpitations or breathlessness,
must stop driving immediately and must notify the
DVLA. Patients with PAH who are under the care of a
specialist centre may only drive after specialist assessment,
and only if the assessment concludes that there is an annual
risk of a disabling event of <20%. The requirements are
even stricter for group 2 licence holders. Failure to disclose
a medical condition that aﬀects driving eligibility can lead to
a ﬁne of up to £1000, and criminal prosecution if driving
results in a road traﬃc collision.
These changes are signiﬁcant. Previously, patients with
either condition could continue to hold a group 1 licence
provided there was ‘‘no other disqualifying condition’’.
Under the new guidance, however, patients with symptomatic
congenital heart disease may face a blanket ban on driving.
Inconsistencies in the guidelines disadvantage our
patients. For example, palpitations are included in the list
of prohibitive symptoms in ACHD. For non-ACHD
patients with arrhythmia, driving must stop only if the
arrhythmia has caused or is likely to cause incapacity.
This creates a double standard – one rule for ACHD
patients and one rule for everyone else.
For PAH, specialist assessment is required to ensure that
the annual risk of a disabling event is <20%. However,
current validated risk stratiﬁcation models only assess over-
all mortality risk; none focus on sudden death or syncope.2–6
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Trial outcomes in PAH do not report ‘annual disabling
event rate’, which makes the provision of meaningful, evi-
dence-based estimates a fool’s errand.
In addition to being evidence-based and fair, obligations
placed upon the health service need to be feasible and cost-
eﬀective. Full implementation of this DVLA guidance,
however, places an unrealistic burden on healthcare practi-
tioners. Additional ‘specialist assessment’ of 5500 adults
with PAH receiving follow-up in dedicated centres7 repre-
sents a large increase in workload. For ACHD specialists,
who are faced with an estimated UK population of 120,000
patients,8,9 the task is even more colossal. Such ‘inclusive’
guidance requires clinicians to make an updated assessment
of driving eligibility in every consultation, with little evi-
dence on how to achieve this in an extremely heterogeneous
population. In ACHD, the same symptom can have widely
diﬀerent implications depending on underlying anatomy.
For example, palpitations due to atrial ﬁbrillation in the
context of a Fontan circulation signals a signiﬁcantly
increased one-year risk of death (non-sudden), whereas
this is not the case for a patient with an atrial septal
defect. Guidance has to be lesion-speciﬁc to reﬂect true
risk. By the same token, symptoms that are not causing
incapacity at the wheel should not aﬀect one’s eligibility to
drive unless there is a disease-speciﬁc cause for concern.
Ultimately, the limitation of the ‘‘law, marching with
medicine but in the rear and limping a little’’ (Lord Justice
Windeyer, 1970)10 should not be replaced by law racing
ahead of scientiﬁc knowledge, leaving a trail of anxious
patients and confused clinicians in its wake. The current
guidance for ACHD and PAH is controversial and signals
the immediate need for collaboration and consensus across
experts nationwide. The goal should be to urgently put in
place practical and easy-to-implement guidance, which
reﬂects current medical knowledge and protects the public
and the patient. Future studies are needed to inform DVLA
guidance. In the meantime, we strongly recommend that
current guidance is urgently revised seeking expert consen-
sus opinion.
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